AB Biosciences (ABB) is dedicated to R&D of niche protein therapeutics for treatment of immune-oncological indications.
The knowledge base in immunoregulation and the technological expertise in protein engineering form the ABB’s core competence in targeting on immune molecules and pushing for versatile therapeutic applications.
PRIM - Recombinant protein as a Pan Fc Receptor Interacting molecule
Cachexian – Cancer treatment via symbiosis with tumor tissues through slowing down the progression of cancer-triggered cachexia.
Abmining – Massive antibody mining, an unique platform for accelerating R&D timelines of therapeutic antibodies.
Déjà vu Mab – Niche platform technology for life cycle maintenance of approved antibody drugs.
NeoCART – Next generation CAR-T modules.